Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

NCT07101497 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Menin Inhibitors
Post Hematopoietic Stem Cell Transplantation
Maintenance Therapy
Acute Leukemia
KMT2A Rearrangement
NPM1 Mutation
NUP98 Gene Rearrangement

Interventions

DRUG: BN104 monotherapy

Sponsor

The First Affiliated Hospital of Soochow University